Seattle-based AltPep Corporation raised $23.15 million in a Series A financing round to take the company’s breakthrough amyloid targeting platform to development.
Rebecca Vaught never set out to become an entrepreneur, but that’s exactly what happened when she launched Van Heron Labs during 2020 with a goal of reframing the understanding of the body’s organismal and cellular performance.
The Renopharma saga for GlaxoSmithKline is one step closer to being settled in court. A Chinese scientist living abroad who has been accused of accepting stolen intellectual property to benefit a pharma startup in China has been extradited to the United States.
Klick Health’s growing commercialization partner portfolio is proud of the successful exit of Circulation, one of Klick’s first incubation initiatives.
Two former executives of Sanofi and Merrimack Pharmaceuticals launched Partner Therapeutics (PTx) to focus on oncology.
Billionaire Mark Cuban invested $250,000 into a small South San Francisco-based biotech company, Perlara, as part of its $7.4 million equity round.
Startup Harmony Biosciences spun out of France-based Paragon Biosciences with $270 million in financing and the exclusive U.S. rights to narcolepsy drug pitolisant.
David Meeker, the former head of rare diseases for Sanofi Genzyme, left the company in 2017 and reappeared at the helm of gene therapy startup KSQ Therapeutics.
Pfizer launched a six-person biotech startup, SpringWorks Therapeutics, with a $103 million Series A financing. Joining Pfizer in funding the company was Bain Capital Life Sciences, Bain Capital Double Impact, OrbiMed and LifeArc, formerly known as MRC Technology.
“This will revolutionize drug development!” or something along those lines is common enough that a high level of skepticism is expected. San Francisco-based Atomwise Inc. is not saying that upfront, but if what they are offering lives up to its potential, it could revolutionize drug development.